Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Abstract: The present invention provides a method of diagnosing APL in a subject which comprises detecting in a sample from the subject either nucleic acid encoding an abnormal RAR-.alpha. receptor or an expressed protein encoded thereby. The present invention also provides methods of identifying a subject with APL who will or will not respond to treatment with a retinoid, as well as a subjects with APL who do not express a detectable t(15;17) translocation but will or will not respond to treatment with a retinoid. In addition, the present invention provides methods for monitoring the activity of APL and the process of treatment of APL. The present invention provides methods of identifying a subject with a neoplastic condition other than APL who will or will not respond to treatment with a retinoid as well as methods for monitoring the level of disease activity and progress and adequacy of treatment of a neoplastic condition.